Skip to main content
    1. Home

    • UCB Medicines: Clinical Studies and Scientific Research Publication

    Publications

    This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.

    Select product(s):
    Select topic(s):
    Phase:

    *Includes seizure clusters and acute or prolonged seizures

    164 result(s)

    phase 4/RWE

    BRIVIACT® (brivaracetam) CV

    Focal Onset Seizures
    View

    Effectiveness and tolerability of 12-month brivaracetam in the real world: EXPERIENCE, an international pooled analysis of individual patient records 

    Vicente Villanueva, Cédric Laloyaux, Wendyl D'Souza et al.  September 09, 2023
    phase 3

    BRIVIACT® (brivaracetam) CV

    Focal Onset Seizures
    View

    Long-term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: an open-label, follow-up trial

    Lieven Lagae, Kerstin Alexandra Klotz, András Fogarasi et al.  September 05, 2023
    phase 3

    FINTEPLA® (fenfluramine)

    Dravet Syndrome
    View

    Fenfluramine in the treatment of Dravet syndrome: results of a third randomized, placebo-controlled clinical trial

    Joseph Sullivan, Lieven Lagae, J Helen Cross et al.  August 17, 2023
    pre clinical

    ZILBRYSQ® (zilucoplan)

    Generalized Myasthenia Gravis
    View

    Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

    Tang Guo-Qing, Tang Yalan, Dhamnaskar Ketki et al.  August 09, 2023
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
    View

    Correction: Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials 

    van der Heijde D, Deodhar Atul, Xenofon Baraliakos et al.  July 03, 2023
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Plaque Psoriasis
    View

    Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis:  Two-year interim results form the open-label extension of the randomized BE RADIANT phase 3b trial.

    Strober Bruce, Paul Carle, Blauvelt Andrew et al.  May 12, 2023
    pre clinical

    FINTEPLA® (fenfluramine)

    Dravet Syndrome, Lennox-Gastaut Syndrome
    View

    Fenfluramine: a plethora of mechanisms?

    Jo Sourbron, Lieven Lagae et al.  May 12, 2023
    phase 3

    ZILBRYSQ® (zilucoplan)

    Generalized Myasthenia Gravis
    View

    Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study

    James F Howard Jr, Bresch Saskia, Genge Angela et al.  May 01, 2023
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Plaque Psoriasis
    View

    Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab, or secukinumab: Results from phase III/IIIb trials.

    Kokolakis Georgios, Warren B. Richard, Strober Bruce et al.  February 22, 2023
    phase 2

    BIMZELX® (bimekizumab-bkzx)

    Psoriatic Arthritis
    View

    Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE 

    Philip J Mease, Akihiko Asahina, Gladman D. Dafna et al.  February 01, 2023